within Pharmacolibrary.Drugs.ATC.L;

model L01EX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.045,
    Cl             = 23.166666666666668,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 1.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.030500000000000003,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Nintedanib is an oral tyrosine kinase inhibitor used primarily for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and as an adjunct therapy for some cancers such as non-small cell lung cancer (NSCLC). It is approved for use in numerous countries, including by the US FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in adult patients (both sexes) with idiopathic pulmonary fibrosis after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Wind, S, et al., &amp; Dallinger, C (2019). Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. <i>Clinical pharmacokinetics</i> 58(9) 1131–1147. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00766-0&quot;>10.1007/s40262-019-00766-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31016670/&quot;>https://pubmed.ncbi.nlm.nih.gov/31016670</a></p></li><li><p>Sgalla, G, et al., &amp; Richeldi, L (2023). BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF). <i>Expert opinion on investigational drugs</i> 32(1) 17–23. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2023.2173061&quot;>10.1080/13543784.2023.2173061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36693635/&quot;>https://pubmed.ncbi.nlm.nih.gov/36693635</a></p></li><li><p>Marzin, K, et al., &amp; Dallinger, C (2018). Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. <i>Journal of clinical pharmacology</i> 58(3) 357–363. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1025&quot;>10.1002/jcph.1025</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29106740/&quot;>https://pubmed.ncbi.nlm.nih.gov/29106740</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX09;
